Your browser doesn't support javascript.
loading
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients / 医学前沿
Frontiers of Medicine ; (4): 285-294, 2022.
Article in English | WPRIM | ID: wpr-929193
ABSTRACT
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cell malignancies. A single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of T cells transduced with CBM.CD19 CAR, a second-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL). Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment. The overall response rate was 20% and 50% at 4 and 12 weeks after the infusion of C-CAR011, respectively, and the disease control rate was 60% at 12 weeks after infusion. Treatment-emergent adverse events occurred in all patients. The incidence of cytokine release syndrome in all grades and grade ⩾ 3 was 90% and 0, respectively, which is consistent with the safety profile of axicabtagene ciloleucel and tisagenlecleucel. Neurotoxicity or other dose-limiting toxicities was not observed in any dose cohort of C-CAR011 therapy. Antitumor efficacy was apparent across dose cohorts. Therefore, C-CAR011 is a safe and effective therapeutic option for Chinese patients with refractory DLBCL, and further large-scale clinical trials are warranted.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: T-Lymphocytes / China / Lymphoma, Large B-Cell, Diffuse / Antigens, CD19 / Receptors, Chimeric Antigen Limits: Humans Country/Region as subject: Asia Language: English Journal: Frontiers of Medicine Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: T-Lymphocytes / China / Lymphoma, Large B-Cell, Diffuse / Antigens, CD19 / Receptors, Chimeric Antigen Limits: Humans Country/Region as subject: Asia Language: English Journal: Frontiers of Medicine Year: 2022 Type: Article